CZ20024175A3 - Systémy a způsoby pro léčbu slizničního povrchu - Google Patents

Systémy a způsoby pro léčbu slizničního povrchu Download PDF

Info

Publication number: CZ20024175A3
Authority: CZ; Czechia
Prior art keywords: amines; carbon atoms; alkyl; irm; irm compound
Prior art date: 2000-06-22

Application number

CZ20024175A

Other languages

Czech (cs)

English (en)

Inventor

John C. Hedenstrom

Michael J. Jozwiakowski

Mark Martinez

Kenneth R. Phares

Kenneth F. Trofatter Jr.

Original Assignee

3M Innovative Properties Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-22

Filing date

2001-06-22

Publication date

2003-06-18

2000-09-29 Priority claimed from US09/676,339 external-priority patent/US6486168B1/en

2001-06-22 Application filed by 3M Innovative Properties Company filed Critical 3M Innovative Properties Company

2003-06-18 Publication of CZ20024175A3 publication Critical patent/CZ20024175A3/cs

Links

210000004400 mucous membrane Anatomy 0.000 title claims description 3
238000000034 method Methods 0.000 title description 31
150000001875 compounds Chemical class 0.000 claims abstract description 94
-1 imidazoquinoline amines Chemical class 0.000 claims abstract description 70
229940124669 imidazoquinoline Drugs 0.000 claims abstract description 21
150000001412 amines Chemical class 0.000 claims abstract description 20
206010008263 Cervical dysplasia Diseases 0.000 claims abstract description 13
230000028993 immune response Effects 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 13
DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 42
210000003679 cervix uteri Anatomy 0.000 claims description 40
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
201000010099 disease Diseases 0.000 claims description 36
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
239000008194 pharmaceutical composition Substances 0.000 claims description 19
206010028980 Neoplasm Diseases 0.000 claims description 11
206010058314 Dysplasia Diseases 0.000 claims description 7
239000003755 preservative agent Substances 0.000 claims description 6
235000014113 dietary fatty acids Nutrition 0.000 claims description 5
239000000194 fatty acid Substances 0.000 claims description 5
229930195729 fatty acid Natural products 0.000 claims description 5
150000004665 fatty acids Chemical class 0.000 claims description 5
230000002335 preservative effect Effects 0.000 claims description 5
230000009826 neoplastic cell growth Effects 0.000 claims description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
230000000670 limiting effect Effects 0.000 claims description 3
QAYNDFKXOSVCGF-UHFFFAOYSA-N [1,3]thiazolo[4,5-c]quinolin-4-amine Chemical compound NC1=NC2=CC=CC=C2C2=C1N=CS2 QAYNDFKXOSVCGF-UHFFFAOYSA-N 0.000 claims description 2
BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 2
150000003222 pyridines Chemical class 0.000 claims 1
208000007951 cervical intraepithelial neoplasia Diseases 0.000 abstract description 4
239000003607 modifier Substances 0.000 abstract description 2
208000014604 Specific Language disease Diseases 0.000 abstract 1
201000007201 aphasia Diseases 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 description 134
125000000217 alkyl group Chemical group 0.000 description 95
239000000203 mixture Substances 0.000 description 78
238000009472 formulation Methods 0.000 description 53
229910052739 hydrogen Inorganic materials 0.000 description 40
239000001257 hydrogen Substances 0.000 description 38
229960002751 imiquimod Drugs 0.000 description 36
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 36
239000000126 substance Substances 0.000 description 32
125000003545 alkoxy group Chemical group 0.000 description 29
238000002360 preparation method Methods 0.000 description 29
238000007906 compression Methods 0.000 description 28
230000006835 compression Effects 0.000 description 28
229910052736 halogen Inorganic materials 0.000 description 25
239000002831 pharmacologic agent Substances 0.000 description 24
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 22
125000004435 hydrogen atom Chemical class [H]* 0.000 description 22
210000001519 tissue Anatomy 0.000 description 22
125000001424 substituent group Chemical group 0.000 description 20
XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 19
150000002367 halogens Chemical class 0.000 description 19
238000011282 treatment Methods 0.000 description 19
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 16
230000001225 therapeutic effect Effects 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 14
125000002768 hydroxyalkyl group Chemical group 0.000 description 14
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 13
241000701806 Human papillomavirus Species 0.000 description 13
125000003342 alkenyl group Chemical group 0.000 description 13
239000003814 drug Substances 0.000 description 13
229920002125 Sokalan® Polymers 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
229940079593 drug Drugs 0.000 description 12
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 12
239000004744 fabric Substances 0.000 description 11
206010008342 Cervix carcinoma Diseases 0.000 description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 10
125000004183 alkoxy alkyl group Chemical group 0.000 description 10
229960001631 carbomer Drugs 0.000 description 10
201000010881 cervical cancer Diseases 0.000 description 10
239000012530 fluid Substances 0.000 description 10
238000011200 topical administration Methods 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
210000001215 vagina Anatomy 0.000 description 9
229960004063 propylene glycol Drugs 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
102000004127 Cytokines Human genes 0.000 description 7
108090000695 Cytokines Proteins 0.000 description 7
230000000259 anti-tumor effect Effects 0.000 description 7
POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 7
230000000694 effects Effects 0.000 description 7
210000003811 finger Anatomy 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
241000700159 Rattus Species 0.000 description 6
125000004423 acyloxy group Chemical group 0.000 description 6
230000000840 anti-viral effect Effects 0.000 description 6
125000000753 cycloalkyl group Chemical group 0.000 description 6
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 6
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 6
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 6
229960002216 methylparaben Drugs 0.000 description 6
239000012071 phase Substances 0.000 description 6
230000004044 response Effects 0.000 description 6
229940075582 sorbic acid Drugs 0.000 description 6
235000010199 sorbic acid Nutrition 0.000 description 6
239000004334 sorbic acid Substances 0.000 description 6
230000000699 topical effect Effects 0.000 description 6
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 5
206010067484 Adverse reaction Diseases 0.000 description 5
102000006992 Interferon-alpha Human genes 0.000 description 5
108010047761 Interferon-alpha Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000006838 adverse reaction Effects 0.000 description 5
125000003118 aryl group Chemical group 0.000 description 5
239000008213 purified water Substances 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
210000003813 thumb Anatomy 0.000 description 5
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 4
125000005041 acyloxyalkyl group Chemical group 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
239000011203 carbon fibre reinforced carbon Chemical group 0.000 description 4
239000002738 chelating agent Substances 0.000 description 4
238000006073 displacement reaction Methods 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 4
125000000623 heterocyclic group Chemical group 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000000622 irritating effect Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
230000003285 pharmacodynamic effect Effects 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
229920001993 poloxamer 188 Polymers 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
VFTLXHXYGQSOEN-UHFFFAOYSA-N 1h-imidazo[4,5-b][1,8]naphthyridine Chemical compound C1=CN=C2NC3=NC=NC3=CC2=C1 VFTLXHXYGQSOEN-UHFFFAOYSA-N 0.000 description 3
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical class NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
102000004889 Interleukin-6 Human genes 0.000 description 3
108090001005 Interleukin-6 Proteins 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000002411 adverse Effects 0.000 description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
239000006071 cream Substances 0.000 description 3
239000011888 foil Substances 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
229940100601 interleukin-6 Drugs 0.000 description 3
230000003902 lesion Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
229910021645 metal ion Inorganic materials 0.000 description 3
BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 3
230000035515 penetration Effects 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000004033 plastic Substances 0.000 description 3
238000004321 preservation Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000000829 suppository Substances 0.000 description 3
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
125000003358 C2-C20 alkenyl group Chemical group 0.000 description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000009608 Papillomavirus Infections Diseases 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
239000004147 Sorbitan trioleate Substances 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
241000700605 Viruses Species 0.000 description 2
QOOXNMYDCWUEHW-UHFFFAOYSA-N [1,3]oxazolo[4,5-h]quinolin-2-amine Chemical class C1=CC=NC2=C(OC(N)=N3)C3=CC=C21 QOOXNMYDCWUEHW-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
125000004965 chloroalkyl group Chemical group 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000002573 colposcopy Methods 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
125000005113 hydroxyalkoxy group Chemical group 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
238000009533 lab test Methods 0.000 description 2
230000004807 localization Effects 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000002175 menstrual effect Effects 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
230000003232 mucoadhesive effect Effects 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
238000011580 nude mouse model Methods 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000035699 permeability Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
229940113124 polysorbate 60 Drugs 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
235000013772 propylene glycol Nutrition 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000007789 sealing Methods 0.000 description 2
229940037001 sodium edetate Drugs 0.000 description 2
239000001587 sorbitan monostearate Substances 0.000 description 2
235000011076 sorbitan monostearate Nutrition 0.000 description 2
229940035048 sorbitan monostearate Drugs 0.000 description 2
235000019337 sorbitan trioleate Nutrition 0.000 description 2
229960000391 sorbitan trioleate Drugs 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
HQBUPOAKJGJGCD-UHFFFAOYSA-N 3h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1=NC2=CC=CC=C2C2=C1N=CN2 HQBUPOAKJGJGCD-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
208000027502 Ankle fracture Diseases 0.000 description 1
206010059313 Anogenital warts Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010061819 Disease recurrence Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
238000000729 Fisher's exact test Methods 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
229940124184 Interleukin receptor agonist Drugs 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
102000005877 Peptide Initiation Factors Human genes 0.000 description 1
108010044843 Peptide Initiation Factors Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
108700025701 Retinoblastoma Genes Proteins 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
206010043515 Throat cancer Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229940060265 aldara Drugs 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
201000004201 anogenital venereal wart Diseases 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
238000004500 asepsis Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000010304 firing Methods 0.000 description 1
125000003709 fluoroalkyl group Chemical group 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000005484 gravity Effects 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000008676 import Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
208000020082 intraepithelial neoplasia Diseases 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000013532 laser treatment Methods 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
229920000092 linear low density polyethylene Polymers 0.000 description 1
239000004707 linear low-density polyethylene Substances 0.000 description 1
229920001684 low density polyethylene Polymers 0.000 description 1
239000004702 low-density polyethylene Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N p-hydroxybenzoic acid propyl ester Natural products CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
108700025694 p53 Genes Proteins 0.000 description 1
238000009595 pap smear Methods 0.000 description 1
239000000123 paper Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229940056099 polyglyceryl-4 oleate Drugs 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000022983 regulation of cell cycle Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
125000005017 substituted alkenyl group Chemical group 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
239000003860 topical agent Substances 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Gynecology & Obstetrics (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CZ20024175A 2000-06-22 2001-06-22 Systémy a způsoby pro léčbu slizničního povrchu CZ20024175A3 (cs)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21342000P	2000-06-22	2000-06-22
US09/676,339 US6486168B1 (en)	1999-01-08	2000-09-29	Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Publications (1)

Publication Number	Publication Date
CZ20024175A3 true CZ20024175A3 (cs)	2003-06-18

Family

ID=26908067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ20024175A CZ20024175A3 (cs)	2000-06-22	2001-06-22	Systémy a způsoby pro léčbu slizničního povrchu

Country Status (17)

Country	Link
EP (1)	EP1296644A2 (et)
JP (1)	JP2004508851A (et)
CN (1)	CN1273110C (et)
AU (1)	AU2001270081A1 (et)
BR (1)	BR0112386A (et)
CA (1)	CA2410208A1 (et)
CZ (1)	CZ20024175A3 (et)
EE (1)	EE200200705A (et)
HR (1)	HRP20021024A2 (et)
HU (1)	HUP0301233A2 (et)
IL (1)	IL153087A0 (et)
MX (1)	MXPA02012524A (et)
NO (1)	NO20026067L (et)
NZ (1)	NZ523073A (et)
PL (1)	PL361975A1 (et)
SK (1)	SK17812002A3 (et)
WO (1)	WO2001097795A2 (et)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0211649D0 (en)	2002-05-21	2002-07-03	Novartis Ag	Organic compounds
CA2502696A1 (en)	2002-10-21	2004-05-06	Mgi Pharma Biologics, Inc.	Compositions and methods for treating human papillomavirus-mediated disease
AU2004284927A1 (en) *	2003-10-22	2005-05-12	University Hospitals Of Cleveland	Method and apparatus for applying medication to internal tissue
JP2008530022A (ja)	2005-02-04	2008-08-07	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫反応調節物質を含む水性ゲル処方物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5939090A (en) *	1996-12-03	1999-08-17	3M Innovative Properties Company	Gel formulations for topical drug delivery
ATE304852T1 (de) *	1999-01-08	2005-10-15	3M Innovative Properties Co	Zubereitungen, umfassend imiquimod oder andere immunantwort modifizierenden verbindungen, zur behandlung von zervikaler dysplasie

2001
- 2001-06-22 HR HR20021024A patent/HRP20021024A2/hr not_active Application Discontinuation
- 2001-06-22 EE EEP200200705A patent/EE200200705A/et unknown
- 2001-06-22 WO PCT/US2001/019979 patent/WO2001097795A2/en not_active Ceased
- 2001-06-22 CA CA002410208A patent/CA2410208A1/en not_active Abandoned
- 2001-06-22 MX MXPA02012524A patent/MXPA02012524A/es active IP Right Grant
- 2001-06-22 NZ NZ523073A patent/NZ523073A/xx unknown
- 2001-06-22 SK SK1781-2002A patent/SK17812002A3/sk not_active Application Discontinuation
- 2001-06-22 BR BR0112386-6A patent/BR0112386A/pt not_active Application Discontinuation
- 2001-06-22 CZ CZ20024175A patent/CZ20024175A3/cs unknown
- 2001-06-22 EP EP01948622A patent/EP1296644A2/en not_active Withdrawn
- 2001-06-22 HU HU0301233A patent/HUP0301233A2/hu unknown
- 2001-06-22 AU AU2001270081A patent/AU2001270081A1/en not_active Abandoned
- 2001-06-22 JP JP2002503272A patent/JP2004508851A/ja not_active Abandoned
- 2001-06-22 IL IL15308701A patent/IL153087A0/xx unknown
- 2001-06-22 CN CNB018115144A patent/CN1273110C/zh not_active Expired - Fee Related
- 2001-06-22 PL PL36197501A patent/PL361975A1/xx not_active Application Discontinuation
2002
- 2002-12-17 NO NO20026067A patent/NO20026067L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL361975A1 (en)	2004-10-18
BR0112386A (pt)	2003-06-10
WO2001097795A3 (en)	2002-04-04
WO2001097795A2 (en)	2001-12-27
HRP20021024A2 (en)	2005-02-28
AU2001270081A1 (en)	2002-01-02
EE200200705A (et)	2004-08-16
NO20026067L (no)	2003-02-17
CN1437463A (zh)	2003-08-20
HUP0301233A2 (hu)	2003-08-28
EP1296644A2 (en)	2003-04-02
JP2004508851A (ja)	2004-03-25
CN1273110C (zh)	2006-09-06
NO20026067D0 (no)	2002-12-17
MXPA02012524A (es)	2003-04-10
NZ523073A (en)	2005-04-29
SK17812002A3 (sk)	2003-05-02
IL153087A0 (en)	2003-06-24
CA2410208A1 (en)	2001-12-27

Publication	Publication Date	Title
US6706728B2 (en)	2004-03-16	Systems and methods for treating a mucosal surface
US6245776B1 (en)	2001-06-12	Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6486168B1 (en)	2002-11-26	Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
EP1495758A2 (en)	2005-01-12	Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US9248127B2 (en)	2016-02-02	Aqueous gel formulations containing immune response modifiers
US20060216333A1 (en)	2006-09-28	Methods related to the treatment of mucosal associated conditions
AU2011285567A1 (en)	2013-03-21	Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
CZ20024175A3 (cs)	2003-06-18	Systémy a způsoby pro léčbu slizničního povrchu
RU2349321C2 (ru)	2009-03-20	Системы и способы лечения поверхности слизистых оболочек
AU2006252154A1 (en)	2007-01-18	Systems and methods for treating a mucosal surface
KR20200020912A (ko)	2020-02-26	항바이러스성 화합물을 포함하는 질내 적용 가능한 장치